Business
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced pre
About this update from Sellas Life Sciences Group, Inc.
[{"type":"image","alt":"SELLAS Life Sciences Group, Inc.","displaySize":"","headline":null,"caption":"SELLAS Life Sciences Group, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/1570633a12e0dc941a3e2343b15473ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GShh9i.pLECdgZkEWUY8Tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1570633a12e0dc941a3e2343b15473ec","width":300,"height":99}},"lazy":false},{"type":"text","content":"- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer –","length":105,"tagName":"p"},{"type":"text","content":"- 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency –","length":119,"tagName":"p"},{"type":"text","content":"NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical efficacy of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer lines. The data are featured in a presentation, entitled “In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines” at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30- June 3, 2025, in Chicago, Illinois.","length":642,"tagName":"p"},{"type":"text","content":"In a panel of cell lines, SLS009 demonstrated potent anti-proliferative activity:","length":81,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In 50% (4/8) of ASXL1 mutant cell lines showed an IC50<100 nM, compared to 0% (0/4) of ASXL1 wild-type lines","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Among cell lines harboring ASXL1 frameshift mutations (FSMs), 75% (3/4) responded with IC50 <100 nM versus only 12.5% (1/8) in cell lines without FSMs","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"All cell lines (3/3) with ASXL1 FSMs in the 637-638 protein region responded to treatment with SLS009","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"In cell lines with IC50 <100 nM, 75% (3/4) also ...